The company has a product development process for all of its medical devices, including a Product Sustainability Review, which is a life-cycle assessment designed to minimize environmental impacts in the early stages of design. Baxter has a wide variety of programs to reduce energy and materials use along with waste and pollution, which has saved the company substantial amounts of money. Baxter’s environmental financial statements make an excellent case for the financial benefits generated by environmental projects. Additionally, Baxter is a corporate leader in addressing climate change with strong greenhouse gas reduction goals.
Baxter currently makes medical products from polyvinyl chloride (PVC) and believes “PVC is the material of choice in many products.” However, the company has also developed and manufactures approximately 300 non-PVC alternatives. Due to the health and environmental concerns regarding PVC products (during manufacturing, use, and disposal), Portfolio 21 is involved in an ongoing dialogue with the company to monitor its progress in the development and marketing of additional non-PVC alternatives.
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 1/31/13 and may not reflect current opinions or subsequent events.